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Abstract 
BACKGROUND: Uterine leiomyoma is a prevalent benign tumor. Several studies have shown the positive effects of 
raloxifene in the treatment of leiomyomas. Since raloxifene has fewer side effects than the gonadotropin-releasing 
hormone (GnRH) agonist, if proven effective, it can be applied easily. This study aimed to compare the medical 
effects of raloxifene and GnRH on uterine leiomyoma size. 
METHODS: This clinical trial included 53 women with uterine leiomyoma. Participants were randomly divided into 2 
groups of raloxifene and GnRH. The GnRH group received 1 dose per month (intramuscular injection) and the 
raloxifene group received 60 mg raloxifene orally/day for 3 months. The size of the leiomyoma, prior and during the 
intervention, was determined by a sonographist. During the study, repeated measurement was used for comparing 
the trend of alterations in the tumor size. 
RESULTS: Analysis of changes in leiomyoma tumor size (log of tumor size) by repeated measurement showed that 
decrease in tumor size in the raloxifene group was significantly higher than GnRH group (P = 0.042). The trends of 
changes in endometrial thickness were different in the 2 groups and the reduction of thickness was more 
significant in the GnRH group (P = 0.026). 
CONCLUSION: This study showed that raloxifene is an appropriate medicine to reduce the size of uterine 
leiomyoma and is more effective than GnRH. 
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Introduction1 
Uterine leiomyoma, also called uterine fibroids, is 
a prevalent benign tumor that affects about 25% 
of women around their menopausal age. This is a 
tumor formed in uterine smooth muscles and 
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approximately one-third of patients have to 
undergo hysterectomy.1 Uterine leiomyoma can 
cause complications such as miscarriage, 
premature labor, detachment of the placenta, and 
bleeding.2,3 
Several non-surgical treatments for the disease 
have been proposed.4,5 Gonadotropin-releasing 
hormone (GnRH) drugs, raloxifene, and letrozole 
are among medications proposed for the 
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treatment of uterine leiomyomas and they are still 
under study.4-10 The hyperestrogenemia state 
induced by GnRH agonist is recognized as an 
effective treatment.1,11 This drug is also associated 
with some side effects including climacteric like 
symptoms, hot flashes, vaginal dryness, 
osteoporosis, and decreased libido.12,13 
Raloxifene is a non-steroidal drug that is 
derived from benzophenone. This drugs is a 
selective estrogen receptor modulator (SERM) 
and acts as an estrogen agonist in the central 
nervous system, and skeletal and cardiovascular 
metabolism; however, it has a weak antagonistic 
effect on breast and uterine activity.14-16 This drug 
also prevents osteoporosis.17 Several studies have 
proved the positive effects of raloxifene in the 
treatment of leiomyomas.8-10 A study by Palomba 
et al., administration of raloxifene had led to the 
reduction of leiomyoma size in menopausal 
women, though it had not been effective in 
premenopausal women.18 There is no other study 
showing the same effect, and the effect of this 
drug is still a controversial issue and more 
research is needed in this area.19,20 
Since raloxifene has fewer side effects than the 
GnRH agonist, if proven effective, it can be 
applied easily. This study aimed to compare the 
medical effects of raloxifene and GnRH on uterine 
leiomyoma size. 
Materials and Methods 
This study was a randomized controlled 
clinical trial (RCT registration code: 
IRCT2014032816490N2) on 53 women with 
uterine leiomyoma referring to the gynecologic 
clinic of Be'sat Hospital in Sanandaj, Iran. In the 
first step, 61 women were evaluated. 8 women 
did not meet our inclusion criteria and were 
excluded from the study (Figure 1). After 
approval of the ethics committee of Kurdistan 
University of Medical Sciences, signed consent 
forms were obtained from all the patients. Then, 
participants were randomly divided into 2 
groups of raloxifene and GnRH using simple 
random sampling method. 
This study included women at child bearing 
age with a history of leiomyomas having a 
minimum size of 40 mm and a maximum of 60 
mm in one dimension. Exclusion criteria 
included history of any metabolic, neoplastic, 
infectious diseases, blood disorders, venous 
thrombosis, liver disease, active rheumatoid 
arthritis, hormone therapy and surgery in the 
last 6 months, hypoechoic mass or calcified 
leiomyomas, endometrial abnormalities in 
sonography, lesions of the cervix and having 
body mass index (BMI) greater than 30 or less 
than 18 kg/m2. 
 
 
Figure 1. Participants profile in raloxifene  
and gonadotropin-releasing hormone (GnRH) groups 
during the study 
 
After random assignment of the patients, the 
GnRH group received 3.75 mg of GnRH/month 
via intramuscular injection, and the raloxifene 
group received a daily dose of 60 mg oral 
raloxifene. Treatment duration was 3 months for 
both groups. Initial investigation and 
administration of drugs were performed by the 
same gynecologist.  
Using transvaginal sonography, our 
sonographist determined the size of leiomyoma 
tumorbefore and three months after intervention. 
The size of leiomyoma was measured in 3 
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dimensions (D1 × D2 × D3 × 0.52). Thebiggest 
leiomyoma was studied when there were more 
than 1 tumor. Furthermore, endometrial thickness 
was measured for each case. Tumor size was 
measured by the same sonographist with no 
knowledge of the type of intervention. We used 
Simadzu SDU 2200 ultrasound machine 
(SIMADU, Japan) for performing sonography.  
Data were entered in SPSS for Windows 
(version 11.5; SPSS Inc., Chicago, IL, USA). We 
used chi-square and Fisher’s exact tests to 
compare qualitative variables and Student’s 
independent t-test and Mann-Whitney test to 
compare quantitative variables between the 2 
groups. During the study, repeated measurement 
was used to detect the changes in the tumor size. 
The sphericity assumption was assessed via 
Mauchly's sphericity test. 
Results 
This study included 53 participants, 27 in the 
raloxifene group and 26 in the GnRH group. Only 
1 participant had history of smoking. Mean age of 
the participants was 42.1 ± 7.9 years, and their age 
ranged from 21 to 51 years; the mean of parity 
was 2.1 ± 1.8. 43 (81.1%) were married and the 
rest were single (virgin, divorced, or widowed). 
In addition, 5 patients (9.4%) had hypertension. 
Menorrhagia was observed in 50 patients (94.3%), 
pelvic pain in 31 patients (58.5%), and flushing in 
7 patients (13.2%). No statistically significant 
differences were observed between the 2 groups 
regarding the above-mentinsed variables  
(Table 1). 
Mean of leiomyoma size (mm3) decreased from 
213.4 ± 356.5 to 77.2 ± 136.8 mm3 in the raloxifene 
group and from 113.4 ± 73.4 to 
96.9 ± 74.6 mm3 in the GnRH group (Table 2). 
Figure 2 indicates analysis of changes in 
leiomyoma tumor size (log of tumour size) by 
repeated measurement. Tumour size was 
significantly higher in the raloxifene group 
compared toGnRH group (P = 0.042). The trends of 
changes in endometrial thickness were different in 
the 2 groups and the reduction of thickness was 
more significant in the GnRH group (P = 0.026). 
 
Table 1. Comparison of individual characteristics 
between raloxifene and Gonadotropin-releasing 
hormone (GnRH) groups 
Variables Raloxifene (n = 27) 
GnRH 
(n = 26) P 
Age 42.4 ± 4.8 39.6 ± 8.2 0.143† 
Parity 1.88 ± 1.39 2.36 ± 2.1 0.68† 
BMI 28.8 ± 5.3 27.7 ± 3.9 0.559† 
Smoking 0 (0%) 1 (3.8%) 0.491†† 
Hypertension 2 (7.4%) 3 (11.5%) 0.669†† 
Married 22 (81.5%) 21 (80.8%) 0.947†† 
Menorrhagia 25 (92.6%) 25 (96.2%) 1†† 
Tension sense 16 (61.5%) 21 (80.8%) 0.126 
Pelvic Pain 15 (57.7%) 15 (57.7%) 1 
Hot flash 5 (19.2%) 2 (7.7%) 0.419†† 
† Mann-Whitney test 
†† Fisher’s exact test 
Others were tested by chi-square test  
GnRH: Gonadotropin-releasing hormone  
BMI: Body mass index 
 
Discussion 
In this study, both groups were similar regarding 
basic variables; however, at the beginning of the 
study the average size of leiomyomas in the 
raloxifene group was bigger than what was found  
 
Table 2. Mean and standard deviation of leiomyoma sizes (mm3) and endometrial thickness (millimeters) during the study 
Indicator  Raloxifene (n = 27) GnRH (n = 26) P† 
Leiomyoma sizes 
Month baseline 213.4 ± 356.5 113.4 ± 73.4 0.042 
Month 1 119.9 ± 204 89.9 ± 71.9  
Month 2 84.7 ± 131.8 83.6 ± 71.9  
Month 3 77.2 ± 136.8 96.9 ± 74.6  
Endometrial thickness 
Month baseline 5.8 ± 1.8 6.2 ± 2.5  
Month 1 5.3 ± 1.6 5.4 ± 2.2 0.026 
Month 2 6.4 ± 8.9 4.7 ± 1.4  
Month 3 4.7 ± 1.1 4.5 ± 1.4  
†
 Repeated measurement; GnRH: Gonadotropin-releasing hormone 
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Figure 2. Trend of leiomyoma sizes (cm3) in raloxifene and Gonadotropin-releasing hormone  
(GnRH) groups during the study 
 
in the GnRH group. The logarithm of tumor size 
was used for improving the precision of the 
statistical tests. Based on the results, prescribing 
raloxifene for 3 months was more effective than 
GnRH in reducing the size of uterine 
leiomyomas. The endometrial thickness had a 
greater reduction in the GnRH group compared 
to the raloxifene group. 
Leiomyomas are estrogen-dependent tumors. 
GnRH is one of the most common drugs used for 
leiomyomas and its effects usually begin within 3 
months.21 Although, GnRH is recognized as an 
effective treatment for reducing the size of 
leiomyoma, vriable results have been reported in 
different studies.5,10,22 GnRH is more effective in 
women under 35 years; therefore, the variations 
in the results of different studies might be 
attributed to age.5 The wide age range in our 
study increased the external validity. This drug, 
which induces hypoestrogenism can cause 
vascular vasoconstriction in leiomyoma, but it 
may also have some other side effects such as 
insulin resistance, hyperlipidemia, and 
osteoporosis. Thus, the long-term administration 
of the drug can lead to several 
complications.12,13,23 Raloxifene is a kind of 
selective estrogen receptor modulator (SERM), 
which can prevent osteoporosis in menopausal 
women.17 This drug can also prevent collagen 
synthesis in leiomyomas.20 Raloxifene decreases 
the proliferation of endometrial tissue and this 
mechanism can affect leiomyomas.24 In our study, 
raloxifene was effective in reducing the size of 
leiomyomas. In some studies, administration of 
an appropriate dose of raloxifene in 
premenopausal women failed to significantly 
reduce the size of leiomyomas.18,25  
However, in a study, the simultaneous 
administration of raloxifene and GnRH for a long 
time (18 cycles) in premenopausal women 
prevented osteoporosis and any increase in the 
levels of glucose and lipids with no special side 
effects. For a better therapeutic effect 6 cycles of 
treatment are necessary. However in our study, 
Raloxifene did not reduce the vasomotor 
symptoms associated with the GnRH.26 In a study 
by Palomba et al., raloxifene had no effect on the 
size of leiomyomas and menstrual bleeding in 
premenopausal women.18  
However, in the raloxifene group we found no 
new case of tumor and no increase in the size of 
tumors. Administration of raloxifene was not as 
0
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effective as GnRH in reducing the size of 
endometrial thickness. Hence, raloxifene is a 
suitable medication for asymptomatic 
postmenopausal women as the drug does not 
have a great effect on the endometrial thickness 
and the vasomotor system.27  
Jirecek et al. showed that raloxifene prevented 
the growth and progress of the leiomyoma; 
however, there was no significant difference in 
the clinical symptoms between the 2 groups and 
the drug was well tolerated.28 Raloxifene can also 
reduce the risk of breast cancer and has a 
beneficial effect on skin elasticity.29,30  
One limitation of our study was that we did 
not assess the signs and symptoms of the patients 
and only the size of leiomyomas was studied. 
Thus, we recommend further studies for 
evaluation of the effect of raloxifene on the 
patient's signs and symptoms. 
Conclusion 
This study showed that raloxifene is an 
appropriate medicine to reduce the size of uterine 
leiomyoma and it is more effective than GnRH. 
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